ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

GALT Galectin Therapeutics Inc

3.45
-0.05 (-1.43%)
After Hours
Last Updated: 17:24:55
Delayed by 15 minutes

Period:

Draw Mode:

Volume 173,928
Bid Price 3.38
Ask Price 3.48
News -
Day High 3.72

Low
1.28

52 Week Range

High
4.2684

Day Low 3.45
Company Name Stock Ticker Symbol Market Type
Galectin Therapeutics Inc GALT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.05 -1.43% 3.45 17:24:55
Open Price Low Price High Price Close Price Prev Close
3.56 3.45 3.72 3.45 3.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,096 173,928 $ 3.55 $ 618,270 - 1.28 - 4.2684
Last Trade Time Type Quantity Stock Price Currency
16:00:00 6,291 $ 3.45 USD

Galectin Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
213.38M 61.85M - 0 -44.81M -0.72 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Galectin Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GALT Message Board. Create One! See More Posts on GALT Message Board See More Message Board Posts

Historical GALT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.343.722.883.30224,2870.113.29%
1 Month2.394.26842.263.56322,2701.0644.35%
3 Months1.744.26841.593.05159,6541.7198.28%
6 Months2.074.26841.5552.66107,7501.3866.67%
1 Year1.764.26841.282.3381,5531.6996.02%
3 Years4.005.701.023.23331,826-0.55-13.75%
5 Years4.755.701.023.03399,415-1.30-27.37%

Galectin Therapeutics Description

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Your Recent History

Delayed Upgrade Clock